Trials / Completed
CompletedNCT00684476
Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Meir Medical Center · Academic / Other
- Sex
- All
- Age
- 6 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Maintenance venom immunotherapy administered at 6-month intervals to bee-venom allergic patients failed to provide protection from systemic reactions after sting challenges. These patients should continue their immunotherapy at 1-3 month intervals.
Detailed description
Background: The intervals at which maintenance venom immunotherapy (MVIT) is administered have been progressively extended over the years. Objective: To examine whether the administration of bee venom (BV) maintenance dose (MD) at 6-month interval is safe and efficacious. Methods: The usual 3-month interval at which venom allergic patients were receiving their MVIT was gradually extended to 6 months. Systemic reactions (SRs) to immunotherapy injections or to field stings were regularly recorded. BV allergic patients were deliberately sting-challenged after reaching the 6-month interval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | venom immunotherapy |
Timeline
- Start date
- 2004-06-01
- Completion
- 2006-05-01
- First posted
- 2008-05-26
- Last updated
- 2008-05-26
Source: ClinicalTrials.gov record NCT00684476. Inclusion in this directory is not an endorsement.